Cinromide (CAS No 58473-74-8) is a compound of interest in neuropharmacological research primarily investigated for its anticonvulsant properties Originating from studies focused on the treatment of epilepsy its mechanism of action involves modulation of sodium channels and enhancement of GABAergic transmission In vitro Cinromide exhibits activity in the nanomolar to low micromolar range demonstrating efficacy in reducing neuronal excitability It is frequently employed in cell models and animal studies to understand its potential as a therapeutic agent particularly in the context of drug-resistant epilepsy Additionally Cinromide is utilized in drug screening assays to evaluate its effectiveness and safety profile Experimental concentrations typically depend on the specific research design allowing for flexibility in dosage determination relative to the study s objectives and required outcomes